The cancer multidisciplinary team meeting: in need of change? History, challenges and future perspectives

David A. Winters1, Tayana Soukup2, Nick Sevdalis1,2, James S.A. Green2 and Benjamin W. Lamb3,4

1Department of Urology, Barts Health NHS Trust, Whipps Cross University Hospital, 2Centre for Implementation Science, Health Service and Population Research Department, King’s College London, London, 3Department of Urology, Cambridge University Hospitals NHS Foundation Trust, and 4Faculty of Health, Education, Medicine and Social Care, School of Allied Health, Anglia Ruskin University, Cambridge, UK

Two decades since their inception, multidisciplinary teams (MDTs) are widely regarded as the ‘gold standard’ of cancer care delivery. Benefits of MDT working include improved patient outcomes, adherence to guidelines, and even economic benefits. Benefits to MDT members have also been demonstrated. An increasing body of evidence supports the use of MDTs and provides guidance on best practice. The system of MDTs in cancer care has come under increasing pressure of late, due to the increasing incidence of cancer, the popularity of MDT working, and financial pressures. This pressure has resulted in recommendations by national bodies to implement streamlining to reduce workload and improve efficiency. In the present review we examine the historical evidence for MDT working, and the scientific developments that dictate best practice. We also explore how streamlining can be safely and effectively undertaken. Finally, we discuss the future of MDT working including the integration of artificial intelligence and decision support systems and propose a new model for improving patient centredness.

Keywords
multidisciplinary teams, decision-making, quality improvement, optimisation, observation, assessment, streamlining, complexity

Why do we have multidisciplinary teams?
Multidisciplinary teams (MDTs) are widely regarded as the ‘gold standard’ of cancer care delivery. The concept of MDT working was introduced >20 years ago to address discrepancies in the quality of care and improve the timely coordination and delivery of care. Since then, the practice of MDT working has been adopted by many countries worldwide. Presentation of cancer cases at MDT meetings (MDTMs) is recommended by a number of professional bodies and international guidelines [1, 2].

The MDT generally consists of histopathologists, radiologists, surgeons, cancer nurse specialists, oncologists, and administrators, also known as MDT coordinators. Depending on tumour type, there may be other members such as chest physicians, haematologists, or allied health professionals. Central to MDT working is the MDTM, where cases are presented, information shared and reviewed, and care management discussed and documented. MDTMs typically occur weekly or fortnightly and can last several hours, with discussion of as many as, on average, 50 cases. The decision-making process in MDTMs should be driven by and is dependent on a combination of holistic and clinical inputs, including the patient history, comorbidities, psychosocial information, patient views on treatment options (if available at the point of the MDTM), pathology, and radiology, along with effective MDTM management [3].

Consistent with the objectives of multidisciplinary care at its inception, demonstrated benefits include improved adherence to best clinical practice, improved timeliness of diagnostics and treatment, and improved patient outcomes, including survival [4, 5]. In addition, other benefits that have become apparent include improved healthcare professional wellbeing, education, and quality assurance [6]. Moreover, the roles of healthcare professionals, e.g. pathologists and radiologists, have become embedded in and integral to the care pathway. The cost-effectiveness of MDT working remains contentious, but evidence is emerging of the financial benefits of MDTs through improvements in the organisation and delivery of care [7]. MDT working is strongly supported by the urological community and is regarded as a driver of improved quality of care. Following success of the MDT model in cancer care, it has now been extended to the management of benign diseases that involve complex care [8]. For instance, MDT working in urology is applied in some NHS Trusts to conditions such as stone management, urinary incontinence, reconstructive urology, and andrology [9].
What makes an MDT Meeting Effective?

Over the past decade, key performance indicators have been generated through research and stakeholder engagement, with high levels of agreement between different cancer teams in terms of what constitutes effective MDT working [10]. Improvement research focussed on cancer MDTs over the past 10 years, mostly in the UK, has provided a ‘tool kit’ with which MDT members can assure and improve the quality of their MDTs. Over this period, research into the workings of cancer MDTs has been undertaken, and an evidence base has been accumulated on the factors that promote or hinder teams to review patients holistically within a MDTM, and make recommendations that are both clinically sound and acceptable to patients [11].

Several evidence-based tools for the assessment and improvement of the performance of MDTs (Table 1; [11–19]) have been developed. These tools can be used by clinicians, administrators, or researchers to gain an objective understanding of how their teams are performing. They can be used as part of an audit or quality improvement initiative to improve the delivery of care for patients, and as an aid to streamlining MDTMs. Of particular relevance at present is an evidence-based stakeholder-driven assessment tool (Measurement of case-Discussion Complexity [MeDiC]) to aid streamlining of MDTMs through patient selection according to specific complexity indicators [20]; this is in line with the most recent initiative by the NHS England and NHS Improvement [21].

These tools can be applied at different points along the MDT pathway: pre-MDTM case selection; for intra-MDTM streamlining; and post-MDTM, for team reflection, assessment and team building (Fig. 1; 23).

Challenges to MDT Meeting Effectiveness

Despite agreement in evidence and opinion on what constitutes MDT meeting effectiveness, variability remains in the functioning of MDTs. For example, in the UK, the Getting It Right First Time (GIRFT) Programme National Speciality Report for Urology found that there is variability between NHS Trusts in regard to treatment recommendations for radical nephrectomy for renal cancer, even accounting for case mix [9]. Such variation in management, if not explained by demographic differences, suggests that some MDTs are not performing optimally.

It is clear from the literature that inefficiencies in existing MDT processes are commonplace [6]. For example, failure of clinicians to submit adequate information at the point of referral means cases are rejected by the MDT and need to be re-presented. Failure to present adequate information means

---

Table 1 | A list of instruments used to assess and improve MDT working

| Instrument (authors or source) | Brief instrument description | Methodology |
|-------------------------------|-------------------------------|-------------|
| MDT-OARS (Taylor et al.) [12] | The MDT Observational Assessment Rating Scale assesses 18 elements of good team functioning as expressed in national UK guidance | Observation |
| TEAM (Taylor et al.) [13] | The Team Evaluation and Assessment Measure assesses core functions of the team and their team meetings, as defined in the characteristics of effective MDT | Team self-assessment |
| MDT-QuIC (Lamb et al.) [14] | The MDT Quality Improvement Checklist is designed to aid decision-making in MDTMs by ensuring that all aspects of a case are reviewed by the team in a structured, evidence-based manner per specialty, and team ability to reach a decision in the MDTM | Checklist |
| MDT-MODe (Lamb et al.) [15] | The MDT Metric of Decision-Making is a tool designed to be used by healthcare professionals to give MDTs insight into the way they work to facilitate improvements in practice | Observation |
| MeDiC (Soukup et al.) [20] | The MeDiC tool of its kind which reliably and validly captures the complexity of cancer cases put forward for MDT discussion is designed to aid decision-making in MDTMs by ensuring that all aspects of a case are reviewed by the team in a structured, evidence-based manner per specialty, and team ability to reach a decision in the MDTM | Observation |
| MDT-FIT (www.mdtfit.co.uk) [19] | The MDT Feedback for Improving Team Working bundles the validated components of MDT-MOT and TEAM to allow self-assessment of team working, combined with expert feedback from facilitator, and sharing of the outcome with the team. | Team self-assessment and observation |

FIT, feedback for improving team-working; MODe, metric of decision-making; MOT, meeting observational tool; OARS, Observational Assessment Rating Scale; TEAM, Team Evaluation and Assessment Measure. Adapted from Soukup et al. [11].

---
recommendations cannot be decided upon; cases with MDT recommendations that are clinically inappropriate or unacceptable to patients cannot be implemented. At each of these junctions, delays in patient care and waste of specialist staff’s time occur with repeated listing for MDTMs, consuming additional resources. Such inefficiencies arise from lack of understanding of what is required for effective clinical decision-making in MDTs. A number of factors were found to have an adverse impact on effective clinical decision-making [11, 22–24]; these include professional hierarchies, lack of open discussion, failure to consider holistic information or patient views, lack of personal knowledge of the patient being discussed, as well as the logistical issues (administrative, process, attendance, and equipment issues), time and workload pressures, fatigue, gender imbalance on the team, and communication practices such as antagonism, tension and un-acknowledgment of other team members contributions. Where MDT working has been studied in detail, these themes have been found to some degree across all tumour types and all locations.

The difficulty MDTs have in achieving their potential is not the fault of the healthcare professionals who work hard for their patients and colleagues, but may instead be a limitation of the system in which we work. MDTs have become burdened by increasing workloads with an unmatched, limited increase in resources to support such work [25–29].

The result is that support services, such as radiology and pathology cannot meet their MDT commitments whilst supporting other essential non-MDT related work. The reasons for growing workload are numerous, including increased cancer incidence, cancer survival, comorbidities, population size, and longevity [11, 25–29]. In addition, perhaps due to the success of the MDT model, many straightforward or non-cancerous cases are put through the MDT meeting [30]. It appears that healthcare professionals appreciate the benefits of the MDT and feel confident in the safety net it provides for a range of cases, although there are growing concerns that clinicians now fear making clinical decisions without the approval of the MDT [31].

**Evolution of the MDT Model**

Recently, there has been a recognition that the current model of MDT working, as is mandated in the UK, needs to evolve. It has been recognised that the concept of reviewing every new cancer case of suspected or confirmed cancer, as well as some cases of recurrence, is not sustainable. A national UK report by Cancer Research UK into the challenges facing cancer MDTs highlighted the discrepancy between the demands placed on, and the resources available to MDTs, while making a number of recommendations for improvement [32, 33]. Subsequently, the UK Government Department of Health and Social Care commissioned a national pilot aimed at transforming the working of cancer MDTs to increase efficiency in the light of the growing service demands [31]. With the guidance on streamlining published by NHS England and NHS Improvement in early 2020, the mandate for discussing all cancer cases no longer exists in the UK [21].

**Focus on Complex Cases**

The greatest benefit of MDT working is seen in complex cases, e.g. unusual subtype of disease, failure of previous treatment, significant comorbidities, social or psychological problems. Indeed, evidence shows that the complex cases yield better quality decision-making and wider contributions to discussion by the participating MDT members [23, 24].
Complexity relating to cases discussed in an MDTM has been scientifically defined as involving patient factors (socio-economic, psychological comorbidity, patient preferences), disease factors (tumour type, stage, grade) and treatment factors (specialist input, toxicity, monitoring, follow-up, trials, conflicting data, application of guidelines) [20]. Indicators of case complexity have been found to be consistent across a range of tumour types [20]. These patients often do not fit guidelines, are not eligible for clinical trials, can be challenging to engage in healthcare services, and may require tailored individualised treatment plans. Although they represent a small portion of cases, a considerable amount of additional support is needed before and after diagnosis and treatment [34].

Most cases discussed in MDTMs are at the point of diagnosis, or treatment initiation, and most MDTMs are chaired by surgeons, with oncologists being less inclined to refer cases of more advanced disease [35]. However, the MDT is the ideal forum for making recommendations about changing treatment strategies for patients with advanced disease on systemic therapy both in terms of clinical- and cost-effectiveness [4, 5, 7]. Patients with advanced disease on systemic therapy are complex for various reasons. For instance, as a patient’s disease progresses, their performance status may decline and the toxicity of systemic treatment increases, the potential benefits of coordinated, holistic MDT working become more apparent. Furthermore, systemic treatments, in particular immune therapies, carry a significant risk of toxicity. Immune-related adverse events are commonplace and can affect any organ. Accordingly, MDTs can provide substantial added value in managing immune-related adverse events and educating healthcare providers about them [36]. In addition, novel agents for treating advanced cancer are generally expensive. Weighing up the benefits and risks of these agents, with limited resources, treatment recommendations should be made carefully under the governance structures that exist in the MDT. Indeed, MDT working has been shown to increase cost-effectiveness [7]. As the complexity and cost of the management of advanced disease increases, the MDT approach becomes both necessary and desirable for these patients and healthcare professionals alike.

Streamlining MDT Working: Case Selection for MDT Presentation

It has been proposed that only complex patients, requiring true multidisciplinary input, would be discussed at MDTMs, whilst patients not meeting criteria for full discussion would be treated according to predetermined/agreed algorithms/guidelines [20, 21, 37]. This would reduce the time all MDT members, especially radiologists and pathologists, spent in MDTMs and actually increase the time such complex patients require for review, which is currently pressurised by the large volumes of simpler cases that are also mandatorily presented at the MDTM (such that urological MDTMs have been shown to spend a median 2–3 min per case discussion, hardly enough for a complex patient [38]). Evidence to support this initiative has been provided by several studies across different tumour types, which have reported reduced number of cases discussed at MDTMs and a reduction in MDTM duration. Two national surveys distributed by Cancer Research UK have shown that 87% of urologists agree that some patients could be managed outside of full MDT discussion [39]. Streamlining has been trialled in Urology across a number of NHS Trusts in the UK, with benefits becoming apparent [21, 31, 33]. For example, at Southport and Ormskirk cases were triaged and 15% not discussed that resulted in a reduction in MDTM duration of ~10 min [9]. This time saving could then be allocated to patients who truly benefit from a multidisciplinary approach, i.e. complex cases. NHS England guidance marked a formal endorsement of streamlining cancer MDTMs in the UK [21]. It may be desirable therefore to scientifically identify cases that are truly ‘complex’ and those that are ‘simple’ using available tools to for stratifying cases by complexity (e.g. the MeDiC tool; [20]).

There are concerns that patients not discussed at the MDT might receive suboptimal care compared to those being discussed. Given the paucity of regular and rigorous audit of MDT outcomes, these concerns should be taken seriously. There is an urgent need to take a scientific approach to streamlining MDT working, whilst at the same time maintaining patient safety and the quality of care. Failure to use best evidence to streamline MDT processes risks reducing workload at the expense of a return to unwarranted variation in patient care, as was the case before the introduction of MDTs in the UK [37, 40]. If this is to be avoided, a comprehensive approach will be needed (Box 1 [37]).

The careful, planned collection of clinical and process data is critical to assess and inform complex areas of healthcare such as care pathways and organisational changes. The recent NHS England and NHS Improvement report has highlighted that data collection and regular audit must accompany MDT transformation [21]. The collection and analysis of such data might provide a resource to benchmark processes and outcomes, thereby driving standardisation and convergence towards best practice [34]. Well-designed data collection supports quality improvement and clinical research, driving the development of new and better standards of care.

The time between MDTMs can present a period of significant stress and anxiety for patients with rapidly progressing disease waiting for MDT review and recommendations [34]. In such cases, the MDT Chair is well placed to endorse management proposals of clinicians.
out with the MDTM in order to avoid delays [34]. Such cases should still be registered with the MDT and could be reviewed post hoc. In order to enable the MDT Chair to assume an enhanced role, in particular as part of streamlining, triaging cases prior to the MDTM, and using the Chair’s action for urgent management, the role needs strengthening. It is important, therefore, that the role has credibility, which could be enhanced by introducing competitive application, and also the necessary resources, by allocating increased time in the job planning for the MDT Chair. Administrative support for the MDT Chair would also need to be enhanced by increasing support and training for MDT coordinators, a professional group critical to effective MDT function, but historically with little training, low retention rates, and currently no professional representation at a national level [41].

The Future Role of Technology in MDT Working

Computerised Clinical Decision Support Systems

As the complexity of cancer care increases, consideration must be given to genomic and molecular information, novel treatments and clinical trials in order to provide patients with precise and high-quality care. Computerised clinical decision-support systems (CDSSs) have been developed to support the quality of care and improve decision-making. At one level, CDSSs capture patient data and identify eligible patients for clinical trials, and suggests evidence-based treatment recommendations [42]. Others may have additional functionality, such as those that can be integrated into electronic medical record (EMR) systems and harness artificial intelligence (AI); with the most advanced being cognitive computing systems that store and index current literature, protocols, and patient charts, learning from cases and improving the performance of the MDT [43–45]. Such systems have demonstrated improvements on process outcomes, such as preparation time and guideline adherence across a number of settings in oncology, including MDTMs. To date, no improvements in clinical outcomes have been demonstrated [46]. Physicians appear to regard CDSSs favourably, with easy access to well-structured data, and reducing the time spent by clinicians on MDTM preparation and duration being desirable features [47]. However, concerns include incomplete or untrustworthy output generated by the system and insufficient adaptability of the system to local and contextual needs [47]. Going forward, CDSSs need further validation against improved clinical outcomes and demonstration of flexibility with application to local healthcare settings [47]. CDSSs have huge potential to improve the consistency of MDT management recommendations and their convergence with guidelines by assisting with the collation of all relevant information for case discussion, highlighting the current evidence base, and providing data on previous management decisions for similar cases. They also offer potential for personalisation of treatment plans with the integration of molecular medicine, genetics and clinical trials, including those beyond the immediate network.

Artificial Intelligence and Machine Learning

Radiologists and pathologists spend significant amounts of time preparing for MDTMs, far in excess of other members of the MDTMs [48]. Whilst endeavours to streamline MDTMs are admirable, they may in fact put more pressure on histopathology and radiology services by demanding further preparation in advance of any triaging activity. The use of AI and machine learning (ML) in these two fields presents a great opportunity to reduce the workload of clinicians by accelerating the process of distinguishing investigations that show benign from malignant disease, as well as improving risk stratification.

Radiology

Convolutional neural network (CNN) algorithms have been applied to improve intra- and interobserver discrepancy in the Prostate Imaging-Reporting and Data System (PI-RADS) scoring from patients who underwent MRIs for suspicion of prostate cancer [49]. Other models have incorporated MRI
radiomics data with Gleason scores to train a ML model to predict clinically significant prostate cancer on MRI images with some success [50]. In renal cancer, ML models have been developed to accurately differentiate benign oncocytomas from RCC [51, 52]. Similarly, AI has been used to help in the planning of surgery by constructing three-dimensional models of renal anatomy from CT scans. [53] Pattern recognition algorithms have been developed both to diagnose bladder cancer on cystoscopy, and also stage urothelial cancer from imaging studies. [54, 55]. To date, studies have been conducted on small samples, and further training on larger datasets is needed to improve accuracy to the level of specialist radiologists, but the results are encouraging.

**Histopathology**

The recently developed AI system, Paige Prostate Alpha, is a detection platform that can be utilised by pathologist to increase sensitivity of detection of prostate cancer on whole-slide images from 74% to 90%, with no significant decrease in specificity [56]. Deep learning systems have also been developed that can outperform pathologists in the application of Gleason scores to prostate cancer [57]. Such systems would work well clinically to screen out benign biopsies and prioritise high-risk biopsies for assessment by pathologists. AI has been used for the assessment of percutaneous renal biopsy to classify RCC subtypes and identify features that predict survival outcomes, as well as assessing the degree of kidney disease in biopsy samples [58–60].

**Genomics**

Advances in genomics may lead to increased precision in the management of certain cancers. Next-generation sequencing has been used to profile tumour DNA profiles provide active sites for targeted therapies [61, 62]. This can be used concurrently with high throughput screening (HTS). HTS has led to significant advances in the pharmacology sector [63]. It makes use of advances in robotics, genetics and data analysis to test potentially millions of different active reagents or antibodies to see if they interact with a target providing a building block in the development of novel therapies. In American Tumour Board Meetings there have been some studies showing that it is feasible to look at genomics to create tailor made cancer treatment regimens to help improve outcomes [64]. DNA sequences of interest could potentially be used alongside AI technology, and in the near future.

**The Use of Videoconferencing to Improve Collaborative Decision-Making**

Videoconferencing has been controversial in MDTMs, with apparent advantages and challenges. Regular regional and even supra-regional MDTMs are not feasible without some form of remote contact [34]. Technology failure and differences in communication styles can present challenges to the quality of MDT decision-making [23, 24]. Perhaps an ongoing effect of the coronavirus disease 2019 (COVID-19) pandemic will be the dramatic shift towards telemedicine, replacing many face-to-face interactions. Many MDTs now manage to operate remotely via video link. It may be desirable to supplement this with periodic face-to-face interaction that permit more nuanced communication regarding performance, operational policy, challenges, and future directions [65].

**A New Strategy to Involve the Patient**

As care pathways in the UK are getting shorter in an attempt to improve the timeliness of diagnosis and treatment for patients, patients often have not formally been given a diagnosis of cancer before their case is reviewed in the MDTM. Accordingly, when patients’ cases are discussed in the MDT, data on their attitudes and preferences are frequently not known, and therefore cannot be incorporated into care management recommendations. Research suggests that this makes MDT recommendations less likely to be put into practice, but in truth little audit or research of the implementation of MDT outcomes has been published [66]. Researchers have been arguing for better representation of patients’ interests in MDT decision-making for some time, but research has consistently shown that patients’ views and holistic aspects of care are consistently underrepresented [3, 10, 11]. In fact, some researchers have tested the feasibility of having patients attending MDTMs [67, 68]. Despite the appeal of this strategy to those who hold strongly to the principles of patient-centred care, in practice in a system that is already under strain there might need to be an alternative way of integrating patients’ interests into MDT decision-making at scale. One such approach might be to accept the difficulty in integrating patient-centred information into the MDTM and to focus instead on the synthesis of a precise biomedical picture in a streamlined MDTM. An enhanced post-MDT clinical consultation could then be focussed on personalising this precise biomedical picture. Resources saved through streamlined MDTMs could be redirected into the post-MDTM consultation involving patients, nurses, surgeons, oncologists and other healthcare professionals in face-to-face discussions. The result might be the application of a more precise clinical diagnosis with a personalised care plan for patients, tailored according to patient preferences, psychosocial circumstances and comorbidities.

**Recommendations and Future Direction**

From the present review we can make a number of recommendations with regards to the future direction of the MDT:
Conclusion

There is little doubt that the delivery of care of patients with urological cancers is enhanced through the cooperation and coordination afforded by a multidisciplinary approach. As the complexity of diagnostic and prognostic information, as well as treatments increases, this approach will become increasingly valuable for these patients specifically, and the health service in general. To allow us to absorb this extra work, changes will be necessary to streamline the MDT process and the MDTM in particular. Strategies for improving and streamlining MDT working have been set out, which may require enhancement of the post-MDTM consultation to ensure patients receive holistic care.

Funding

Nick Sevdalis research is funded by the National Institute for Health Research (NIHR) via the ‘Applied Research Collaboration: South London’ at King’s College Hospital NHS Foundation Trust, London, UK. Nick Sevdalis is also a member of King’s Improvement Science, which offers co-funding to the NIHR ARC South London and is funded by King’s Health Partners (Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, King’s College London and South London, and Maudsley NHS Foundation Trust), and the Guy’s and St Thomas’ Charity. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the review. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.

Tayana Soukup is supported by the Welcome Trust and Diabetes UK. David A. Winters, Benjamin W. Lamb, and James S.A. Green received no funding for this work.

Disclosure of Interests

Benjamin W. Lamb and Tayana Soukup have previously received funding from Health Education England and Cancer Alliances for training cancer MDTs in assessment and quality improvement methods in the UK. Tayana Soukup also received fees from Roche Diagnostics for research services in relation to innovations for cancer MDTs in the USA. Nick Sevdalis is the Director of London Safety and Training Solutions Ltd, which provides team working, patient safety and improvement skills training and advice on a consultancy basis to hospitals, training programmes and pharmaceutical companies in the UK and internationally. James S.A. Green is a Director of Green Cross Medical Ltd that developed MDT FIT for use by National Health Service Cancer Teams in the UK. David A. Winters has no competing interests to declare.

References

1 Cancer Institute New South Wales. NSW cancer plan 2016 [Internet]. Cancer.nsw.gov.au, 2016. Available at: https://www.cancer.nsw.gov.au/getsmedia/69ca5241-3620-4898-a32b-e17c7e8c8b9b/CancerPlan2016-Web.pdf. Accessed February 2021
2 Independent Cancer Task Force. Achieving world-class cancer outcomes: a strategy for England 2015–2020 [Internet]. England.nhs.uk, 2020. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancertransformation-programme-2016-17-progress.pdf. Accessed February 2021
3 Soukup T, Petrides K, Lamb BW et al. The anatomy of clinical decision-making in multidisciplinary cancer meetings: a cross-sectional observational study of teams in a natural context. Medicine 2016; 95: e3885
4 Lamb B, Brown K, Nagpal K, Vincent C, Green J, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol 2011; 18: 2116–25
5 Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ 2012; 344: e2718
6 Taylor C, Ramirez AJ. Multidisciplinary Team Members’ Views about MDT Working: Results from a Survey Commissioned by the National Cancer Action Team. London: NHS National Cancer Action Team, 2009
7 Edney LC, Gray J, Karnon J. A scoping review of the economics of multidisciplinary teams in oncology care. J Cancer Policy 2020; 26: 100257
8 National Institute for Clinical Excellence. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE guideline (CG121), 2004
9 Harrison S. Urology: GIRFT programme national specialty report. Get it right first time/NHS improvement, 2018
10 Lamb BW, Taylor C, Lamb JN et al. Facilitators and barriers to teamworking and patient centereredness in multidisciplinary cancer teams: findings of a national study. Ann Surg Oncol 2013; 20: 1408–16
11 Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JS. Successful strategies in implementing a multidisciplinary team working in the care of
patients with cancer: an overview and synthesis of the available literature. J Multidiscip Healthc 2018; 11: 49
12 Taylor C, Brown K, Lamb B, Harris J, Sevdalis N, Green JS. Developing and testing TEAM (Team Evaluation and Assessment Measure), a self-assessment tool to improve cancer multidisciplinary teamwork. Ann Surg Oncol 2012; 19: 4019–27
13 Taylor C, Atkins L, Richardson A, Tarrant R, Ramirez AJ. Measuring the quality of MDT working: an observational approach. BMC Cancer 2012; 12: 202
14 Lamb BW, Sevdalis N, Vincent C, Green JS. Development and evaluation of a checklist to support decision making in cancer multidisciplinary team meetings: MDT-QuIC. Ann Surg Oncol 2012; 19: 1759–65
15 Lamb BW, Miah S, Stewart GD et al. Development and validation of a short version of the metric for the observation of decision-making in multidisciplinary tumor boards: MODe-Lite. Ann Surg Oncol 2021 (Online ahead of print). https://doi.org/10.1245/s10434-021-09989-7
16 Lamb BW, Green JS, Benn J, Brown KF, Vincent CA, Sevdalis N. Improving decision-making in multidisciplinary tumor boards: prospective longitudinal evaluation of multicomponent intervention for 1,421 patients. J Am Coll Surg 2013; 2173: 412–20
17 Jalil R, Soukup T, Akhter W, Sevdalis N, Green JS. Quality of leadership in multidisciplinary cancer tumor boards: Development and evaluation of a leadership assessment instrument (ATLAS). World J Urol 2018; 36: 1031–8
18 Harris J, Taylor C, Sevdalis N, Jalil R, Green JS. Development and testing of the cancer multidisciplinary team meeting observational tool (MDT-MODe). Int J Qual Health 2016; 28: 332–8
19 Taylor C, Harris J, Sterk-K, Sevdalis N, Green JS. A multi-method evaluation of the implementation of a cancer teamwork assessment and feedback improvement programme (MDT-FIT) across a large integrated cancer system. Cancer Med 2021; 10: 1240–52
20 Soukup T, Morbi A, Lamb BW et al. A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the McDwc tool. Cancer Med 2020; 9: 5143–54
21 NHS England and NHS Improvement. Streamlining multi-disciplinary team meetings [Internet], 2020. Available at: https://www.england.nhs.uk/wp-content/uploads/2020/01/multi-disciplinary-team-streamlining-guidance.pdf. Accessed February 2021
22 Soukup T, Lamb BW, Weigl M, Green JS, Sevdalis N. An integrated literature review of time-on-task effects with a pragmatic framework for understanding and improving decision-making in multidisciplinary oncology team meetings. Front Psychol 2019; 10: 1245
23 Soukup T, Lamb BW, Morbi A et al. A multicentre cross-sectional observational study of cancer multidisciplinary teams: analysis of team decision making. Cancer Med 2020; 9: 7083–99
24 Soukup T, Lamb BW, Shah NJ et al. Relationships between communication, time pressure, workload, task complexity, logistical issues and group composition in transdisciplinary teams: a prospective observational study across 822 cancer cases. Front Commun 2020; 5: S83294
25 Fosker CJ. The cost of the MDT. BMJ 2010; 340: c951
26 Aragon MJ, Casterelli A, Gaughan J. Hospital Trusts productivity in the English NHS. PLoS One 2017; 12: e0182253
27 Mistry M, Parkin DM, Ahmad AS et al. Cancer incidence in the UK, Br J Cancer 2011; 105: 1795–803
28 NHS England. Everyone Counts: Planning for Patients 2014/2015 to 2018/2019. London: NHS England, 2014
29 NHS Improvement. Evidence from NHS Improvement on Clinical Staff Shortages: A Workforce Analysis. London: NHS Improvement, 2016
30 Soukup T, Murtagh G, Lamb BW, Green JS, Sevdalis N. Degrees of multidisciplinarity underpinning care planning for patients with cancer in weekly multidisciplinary team meetings: conversation analysis. J Multidiscip Healthc 2021; 14: 411–24
31 Gore M. Transforming Multidisciplinary Team Meetings (MDTM)s [Internet]. England.nhs.uk, 2017. Available at: https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2018/10/Transforming-MDTM-Martin-Gore-August-2017.pdf. Accessed February 2021
32 Cancer Research UK. Improving the effectiveness of multidisciplinary team meetings in cancer services [Internet]. Cancerresearchuk.org, 2017. Available at: https://www.cancerresearchuk.org/sites/default/files/full_report_meeting_patients_needs_improving_the_effectiveness_of_multidisciplinaryチーム_meetings_pdf.pdf. Accessed February 2021
33 Hoinville L, Taylor C, Zasada M, Warner R, Pottle E, Green J. Improving the effectiveness of cancer multidisciplinary team meetings: a national survey of MDT members’ opinions about streamlining patient discussions. BMJ Open Qual 2019; 8: e000631
34 Shamash J, Ansell W, Alifrangis C et al. The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). Br J Cancer 2021; 124: 368–74
35 Lamb B, Payne H, Vincent C, Sevdalis N, Green JS. The role of oncologists in multidisciplinary cancer teams in the UK: an untapped resource for team leadership? J Eval Clin Pract 2011; 17: 1200–6
36 Kennedy LC, Wong KM, Kamat NV et al. Untangling the multidisciplinary care web: streamlining care through an immune-related adverse events (IRAE) tumor board. Targeted Oncology 2020; 15: 541–8
37 Soukup T, Lamb BW, Sevdalis N, Green JS. Streamlining cancer multidisciplinary team meetings: overview of challenges with a guide to capitalizing on existing solutions. Br J Hosp Med 2020; 81: 1–6
38 Lamb BW, Wong HW, Vincent C. Teamwork and team performance in multidisciplinary cancer teams: development of an observational assessment tool. BMJ Qual Saf 2013; 20: 849–56
39 Warner R, Hoinville L, Pottle E, Taylor C, Green JS. Refocusing cancer multidisciplinary team meetings in the United Kingdom: comparing urology with other specialties. Ann R Coll Surg Engl 2021; 103: 10–7
40 Department of Health. A policy framework for commissioning cancer services: a report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales Department of Health [Internet], 1995. Available at: https://webarchive.nationalarchives.gov.uk/20130123204024/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4071083. Accessed February 2021
41 Jalil R, Lamb B, Russ S, Sevdalis N, Green JS. The cancer multidisciplinary team from the co-ordinators’ perspective: results from a national survey in the UK. BMC Health Serv Res 2012; 12: 1–8
42 Patkar V, Acosta D, Davidson T, Jones A, Fox J, Keshtgar M. Using computerised decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidance. BMJ Open 2012; 2: e000439
43 Hamner RD, Fowler D, Sheets LR, Siadimas A, Guo C, Prime MS. Digital Tumor Board Solutions have significant impact on case preparation. JCO Clin Cancer Inform 2020; 4: 757–68
44 Kim MS, Park HY, Kho BG et al. Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board. Transl Lung Cancer Res 2020; 9: 507
45 Puyter JR, Jacobs I, Langereis S et al. Looking through the eyes of the multidisciplinary team: the design and clinical evaluation of a decision support system for lung cancer care. Transl Lung Cancer Res 2020; 9: 1422
46 Klarenbeek SE, Weekenstroo HH, Sedehaar JP, Füttener JJ, Prokop M, Tummers M. The effect of higher level computerized clinical decision support systems on oncology care: a systematic review. Cancer 2020; 12: 1032
Identification of solid renal masses on contrast-enhanced computed tomography images using convolutional neural network with decision fusion. Eur Radiol 2020; 30: 5183–90

Boukhriss B, Kobi BA, Khelifi F et al. Automated renal cancer grading using nuclear pleomorphic patterns. JCO Clin Cancer Inform 2018; 2: 1–2

Tabibu S, Vinod PK, Jawahar CV. Pan-renal cell carcinoma classification and survival prediction from histopathology images using deep learning. Sci Rep 2019; 9: 10509

50 Hectors SJ, Cherny M, Yadav KK et al. Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. J Urol 2019; 202: 498–505

51 Baghdadi A, Aldhaam NA, Elsayed AS et al. Automated differentiation of benign renal oncocytoma and chromophoberal cell carcinoma on computed tomography using deep learning. BJU Int 2020; 125: 553–60

52 Zabihollahy F, Schieda N, Krishna S, Ukwatta E. Automated classification of solid renal masses on contrast-enhanced computed tomography images using convolutional neural network with decision fusion. Eur Radiol 2020; 30: 5183–90

53 Heller N, McSweeney S, Peterson MT et al. An international challenge to use artificial intelligence to define the state-of-the-art in kidney and kidney tumor segmentation in CT imaging. J Clin Oncol 2020; 38(Suppl): 626

54 Sudakoff GS, Dunn DP, Guralnick ML et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008; 179: 862–7

55 Garapati SS, Hadijsikli I, Cha KH et al. Urinary bladder cancer staging in CT urography using machine learning. Med Phys 2017; 44: 5814–23

56 Raciti P, Sue J, Ceballos R et al. Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies. Mod Pathol 2020; 33: 2058–66

57 Bulten W, Pinckaers H, van Boven H et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol 2020; 21: 233–41

58 Holdbrook DA, Singh M, Choudhury Y et al. Automated renal cancer grading using nuclear pleomorphic patterns. JCO Clin Cancer Inform 2018; 2: 1–2

59 Tabibu S, Vinod PK, Jawahar CV. Pan-renal cell carcinoma classification and survival prediction from histopathology images using deep learning. Sci Rep 2019; 9: 10509

60 de Bel T, Hermsen M, Smeets B, Hilbrands L, van der Laak J, Litjens G. Automatic segmentation of histopathological slides of renal tissue using deep learning. Proc SPIE 2018; 10581: 1058112–8. https://doi.org/10.1117/12

61 Drilon A, Laethis TW, Kummar S et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med 2018; 378: 731–9

62 Okamura R, Boichard A, Kato S, Sicklick JK, Bashenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018; 2: 1–20

63 Attene-Ramos MA, Austin CP, Xia M. Encyclopedia of Toxicology, 3rd edn. Waltham, MA: Academic Press, Imprint of Elsevier, 2014: 916–7

64 Kato S, Kim KH, Lim HJ et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun 2020; 11: 1–9

65 Soukup T, Sevdalis N, Green JS, Lamb BW. Quality improvement for cancer multidisciplinary teams: lessons learned from the Anglian Germ Cell Cancer Collaborative Group. Br J Cancer 2021; 124: 313–4

66 Raine R, Xanthopoulou P, Wallace I et al. Determinants of treatment plan implementation in multidisciplinary team meetings for patients with chronic diseases. BMJ Qual Saf 2014; 23: 867–76

67 Lamb BW, Jalil RT, Shah S et al. Cancer patients’ perspectives on multidisciplinary team working: an exploratory focus group study. Urol Nurs 2014; 34: 83–91

68 Heuser C, Diekmann A, Schellenberger B et al. Patient participation in multidisciplinary tumor conferences from the providers’ perspective: is it feasible in routine cancer care? J Multidiscip Healthc 2020; 13: 1729

Correspondence: Tayana Soukup, Centre for Implementation Science|Health Service and Population Research Department, Kings College London, 18 De Crespigny Park, London, SE5 8AF, UK.

e-mail: tayana.soukup@kcl.ac.uk

Abbreviations: AI, artificial intelligence; CDSS, clinical decision-support system; HTS, high throughput screening; MDT(M), multidisciplinary team (meeting); MeDiC, Measure of case-Discussion Complexity; ML, machine learning.